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The accumulation of advanced glycation end products (AGE)
is a key factor in diabetic nephropathy (DN). Pyridoxamine
inhibits AGE formation and protects against type I DN. Herein
we tested: (1) whether C57BL6 db/db mice as a model of
established type II DN resembled patients treated with drugs
which inhibit angiotensin II action; (2) whether pyridoxamine
was effective as a single therapy; and (3) whether
pyridoxamine would add to the benefit of angiotensin-
converting enzyme inhibition (ACEi) by enalapril. In first set
of experiments mice were treated with ACEi (benazepril) and
an angiotensin II receptor blocker (valsartan) combination for
16 weeks after the onset of diabetes. In second group, mice
with established DN were treated with pyridoxamine for 8
weeks. In a third set, mice with established DN were treated
with pyridoxamine and enalapril combination for 16 weeks.
Benazepril and valsartan combination partially prevented the
development and progression of DN. Pyridoxamine
treatment, as single therapy, decreased the progression of
albuminuria and glomerular lesions. The combination of
pyridoxamine with enalapril reduced both mortality and the
progression of DN. In conclusion, (1) C57 BL6 db/db mice are
a model of progressive type II DN; (2) The combination of
pyridoxamine with enalapril decreased progression of type 2
DN and overall mortality. Thus, pyridoxamine could be a
valuable adjunct to the current treatment of established type
II DN.
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Type II diabetic nephropathy (DN) is a major cause of end-
stage renal disease and its prevalence is rising.1,2 While not
the only factor, hyperglycemia has been shown to play a
central role in the development and progression of DN. The
means by which hyperglycemia induces renal changes
involves multiple pathways, including activation of protein
kinase C, increased reactive oxygen species, and accumula-
tion of advanced glycation end products (AGE).3–8 AGE are
derived from a non-enzymatic chemical reaction between
carbohydrates and proteins, lipids or DNA.9 The rate of AGE
formation in serum and tissues is significantly increased in
patients with diabetes, due to the availability of excess free
sugar. We found that the infusion of bovine serum albumin-
derived AGE, formed in vitro, induced glomerular lesions in
normal animals.10 The lesions resembled those found in DN.
The suppression of AGE formation by aminoguanidine
decreased albuminuria and the severity of glomerular lesions
in diabetic rats.11,12 Similar effects were found in diabetic
animals treated with other AGE inhibitors.13,14 Recently,
Hudson et al. found that pyridoxamine, a non-toxic, safe,
and well-tolerated vitamer from the B6 family, inhibited the
glycoxidative breakdown of Amadori products to AGE, a key
step in final AGE formation.5,15 Pyridoxamine treatment
prevented the rise of plasma creatinine levels, albuminuria,
and glomerular hypertrophy in rats with streptozotocin-
induced type I diabetes mellitus.16,17 We postulated that
pyridoxamine would reduce the rate of progression in type II
diabetics with nephropathy. We selected C56BL6 (B6) db/db
mice as the experimental model because 75% of them
develop persistent hyperglycemia and hyperinsulinemina.18
In addition, all of those with persistent hyperglycemia
develop progressive DN. Since the inhibition of angiotensin
II action with either angiotensin-converting enzyme inhibi-
tors (ACEi) or angiotensin II receptor blockers (ARB) has
been shown to reduce the progression of nephropathy in
patients with type II diabetics,19–22 we first asked whether the
response to these drugs in diabetic db/db B6 mice resembled
that in patients. We then asked whether pyridoxamine was
effective as a single agent in these mice and finally, whether
the addition of pyridoxamine would add to the benefits of
ACEi treatment. Since many type II diabetics have already
developed DN before they seek medical advice, we started
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treatment with pyridoxamine or the combination of
pyridoxamine and ACEi (enalapril) in B6 db/db mice 6–7
weeks after they had evidence of established DN.
RESULTS
General characteristics of B6 db/db mice
We examined the natural history of diabetes and nephro-
pathy in 43 female B6 db/db mice. Seventy percent of them
developed diabetes at 7–9 weeks of age, 95% had diabetes at
10–14 weeks of age, and all had developed diabetes at 15–24
weeks of age. Body weight increased for a period of 8 weeks
after diabetes became established, and remained stable or
increased only slightly thereafter. Serum insulin and leptin
levels were increased in diabetic mice.18 Islet hypertrophy was
evident but there was no insulitis in mice up to 8 months of
age (data not shown). Serum cholesterol and triglyceride
levels were increased in diabetic db/db mice (data not
shown). The mice remained normotensive. Urine albumin
excretion increased in B6 db/db mice after 6 weeks of
hyperglycemia (n¼ 31, albumin/creatinine, 0.1170.03 vs 6–8
weeks old, non-diabetic B6 db/db mice, 0.0570.01, Po0.05,
Figure 1a). A further increase in urine albumin excretion was
found in mice after 22 weeks of diabetes (0.2570.06 vs
0.1170.03 at 6 weeks, Po0.05). In contrast, mice that
returned to normoglycemic did not develop progressive
albuminuria.18 Diabetic glomerulopathy in db/db mice is
characterized by mesangial expansion, hypercellularity, and
thickened glomerular basement membranes by light micro-
scopy.18 Very few nodules were identified. Glomerular
hypertrophy, increased cell number, and mesangial matrix
expansion (increased mesangial/glomerular fractional area)
were present as early as 6 weeks after the onset of
hyperglycemia (Figure 1b–d). The lesions were more severe
after 22 weeks of diabetes (Figure 7a).
Combination therapy with benazepril and valsartan
prevented the progression of DN
To test the effectiveness of ACEi and ARB combination on
the development and progression of DN, female B6 db/db
mice with stable hyperglycemia (X200 mg/dl) between 8 and
10 weeks of age were randomized to receive 16 weeks of
treatment with either benazepril plus valsartan (n¼ 10,
15 mg/kg/day of each drug in drinking water) or vehicle
(n¼ 9).
General: Body weight was similar between vehicle
(48.1970.8 g) and the combination therapy groups
(49.0771.3 g) after 16 weeks of treatment (B25 weeks of
age). There were no differences in glycemic and glycosylated
hemoglobin levels between the two groups. Blood pressure
was normal in the vehicle group. Benazepril plus valsartan
treatment did not reduce blood pressure.
Albuminuria: Urine albumin excretion was significantly
increased in the vehicle group after 16 weeks of hyperglyce-
mia (0.2270.05 vs mice before the treatment, 0.0570.01,
Po0.01). Combination therapy with benazepril and valsar-
tan partially prevented the increase in urine albumin
excretion (Figure 2a).
Histology and morphometry: Glomeruli from the vehicle
group showed changes characteristic of DN, including
increased glomerular size and mesangial expansion and
hypercellularity (Figure 2b). The glomeruli were smaller and
extracellular matrix expansion and hypercellularity were less
accentuated after 16 weeks of treatment. Morphometric
analysis showed that the glomerular volume and mean
mesangial area were significantly decreased in the therapy
group compared with the vehicle group (Figure 2b–e).
Pyridoxamine treatment decreased the progression of DN
As described in Materials and Methods, renal biopsies were
performed in this group of animals 6 weeks after the onset of
diabetes. All diabetic mice developed nephropathy at this
time point, as evidenced by increased urine albumin
excretion and glomerular hypertrophy, mesangial matrix
expansion and hypercellularity (Figure 1a–d). Thus, we
started pyridoxamine treatment 1 week after renal biopsy.
General: Food and water intake were similar between
vehicle- and pyridoxamine-treated diabetic db/db mice
during 8 weeks of follow-up. There were no differences in
body weight, glycemic, and glycosylated hemoglobin levels
between mice treated with vehicle and pyridoxamine at the
end of study (23–25 weeks of age). The mice remained
normotensive. Serum cholesterol and triglyceride levels were
not significantly decreased by pyridoxamine treatment (data
not shown). The mean serum pyridoxamine concentration
was increased about fivefold in pyridoxamine-treated mice.
Fifty percent of the mice died in the groups treated with
0
1
2
3
G
lo
m
er
ul
ar
 v
ol
um
e
(×1
05
 
m
3 )
*
0
0.10
0.15
0.05
Ur
in
e 
al
bu
m
in
/
cr
e
a
tin
in
e
*
0
10
20
30
M
es
an
gi
al
/g
lo
m
er
ul
ar
 
a
re
a
 (%
)
*
a
c d
Before 6 weeks
Before 6 weeks Before 6 weeks
b
Figure 1 | Diabetic nephropathy was evident 6 weeks after the
onset of hyperglycemia. (a) Increased urine albumin excretion.
*Po0.05 vs mice before the onset of diabetes. (b) Renal biopsy at this
time revealed increased glomerular size, moderate matrix expansion
and an increased number of cells in the mesangial areas (periodic
acid Schiff 400). (c) Glomerular volume was increased. *Po0.05 vs
prior to the onset of diabetes. (d) Mesangial area was also increased.
The fractional mesangial area was expressed as the ratio of mesangial
and glomerular surface area (%). *Po0.05 vs mice before the onset of
diabetes.
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pyridoxamine and vehicle. Autopsy showed that pulmonary
infection was the most frequent cause of animal death
although the pathogen(s) were not defined. Complications
following the open renal biopsy might have increased the
number of infections observed in this group since most of the
deaths occurred within 2–3 weeks after biopsy. Weight loss
(X5 g) was also a prominent feature of mice with infections.
Mice whose death was due to obvious infections were
excluded from the data analysis, except for overall mortality.
Albuminuria: At killing, urine albumin excretion was
increased 2.3-fold from the onset of treatment in the vehicle
group. Albuminuria was not increased in pyridoxamine-
treated mice (Figure 3).
Histology and morphometry: Vehicle-treated diabetic db/db
mice developed severe, diffuse glomerular lesions consisting
of an increase in glomerular size and mesangial matrix
(Figure 4a). These lesions were much less evident in
pyridoxamine-treated mice (Figure 4b). Marked vascular
pole scarring was frequently seen. Glomerular volume was
increased 6 weeks after the onset of hyperglycemia, and was
further increased after 15 weeks of hyperglycemia in all
vehicle-treated mice (4.170.3 105 mm3 vs 6 weeks,
2.470.2 105 mm3, Po0.01, Figure 4c). In contrast, no
significant increase in glomerular volume from 6 to 15 weeks
after hyperglycemia developed in pyridoxamine-treated mice
(6 weeks, 2.570.4 105 mm3, 15 weeks, 370.5 105 mm3,
P40.05). There was a progressive increase in mesangial area
after the onset of diabetes in vehicle-treated mice (15 weeks,
39.0471.6% vs 6 weeks, 27.671.1%, Po0.05). A further
increase, over a period of 8 weeks, was largely prevented by
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Figure 2 | Benazepril and valsartan combined therapy prevented
the progression of diabetic nephropathy. Mice were treated with
combination or vehicle immediately after the onset of diabetes.
(a) Urine albumin excretion was decreased by the therapy
(benazepril¼ Bena, Vals¼ valsartan). *Po0.05 vs vehicle group.
(b and c) Glomerular lesions were less severe in the treated group.
Glomeruli from the vehicle group were large and the mesangial
regions were expanded. Glomeruli in the therapy group were smaller
in size and had reduced mesangial hypercellularity and sclerosis
(periodic acid Schiff 200). (d) Glomerular volume was decreased in
therapy group. **Po0.01 vs vehicle-treated mice. (e) Mesangial area
expansion was decreased in therapy group. **Po0.01 vs vehicle-
treated mice.
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Figure 3 | Albuminuria did not increase after pyridoxamine
treatment. Urine albumin excretion was increased from 6 to 15
weeks after the onset of hyperglycemia in vehicle-treated mice, but
not in pyridoxamine-treated mice. *Po0.05 vs mice before treatment
or in pyridoxamine-treated mice at study end.
Pyridoxamine
PAS ( × 200) PAS ( × 200)
a b
c d
1
2
3
4
5
1
2
3
4
5
20
10
30
40
50
0
*
P < 0.05
Vehicle
Vehicle Pyridoxamine
6 weeks 15 weeks 6 weeks 15 weeks
G
lo
m
er
ul
ar
 v
ol
um
e
(× 
10
5 

m
3 )
M
es
an
gi
al
/g
lo
m
er
ul
ar
a
re
a
 (%
)
Vehicle Pyridoxamine
Figure 4 | Glomerular lesions were less prominent following
pyridoxamine treatment. (a) After 15 weeks of persistent
hyperglycemia, there was marked glomerular hypertrophy and matrix
expansion in vehicle-treated mice (B24 weeks of age) (periodic
acid Schiff 200). (b) Glomerular lesions were less severe in
pyridoxamine-treated mice (periodic acid Schiff 200). (c) Glomerular
volume was increased from 6 to 15 weeks after diabetes in
vehicle-treated mice. This increase was blocked by pyridoxamine
treatment (Po0.05 vs vehicle-treated mice at 15 weeks). (d)
Mesangial area expansion was less in pyridoxamine-treated mice.
*Po0.05 vs vehicle-treated mice.
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pyridoxamine treatment (30.870.9 vs 27.671.1% at biopsy,
P40.05, Figure 4d).
Combination therapy (16 weeks duration) with enalapril and
pyridoxamine reduced both mortality and the progression of
DN, whereas enalapril therapy did not
After DN was established, B6 db/db mice were randomized to
receive (1) enalapril (10 mg/kg/day) plus pyridoxamine
(250 mg/kg/day); (2) enalapril (10 mg/kg/day) plus pyridox-
amine (100 mg/kg/day); (3) enalapril (10 mg/kg/day); or
(4) vehicle. Mice were followed for 16 weeks. The outcomes
were very similar in mice those received 250 mg/kg/day or
100 mg/kg/day of pyridoxamine, in combination with ACEi,
treatment groups. Since four mice in the group of enalapril
plus 250 mg/kg/day of pyridoxamine became normoglycemic
shortly after treatment was begun, we present results here
only from mice treated with enalapril plus 100 mg/kg/day of
pyridoxamine.
General: Food and water intake were similar among all
groups. There were no significant differences in body weight
in mice at study end (data not shown). All diabetic db/db
mice, including those treated with enalapril, remained
normotensive. Blood glucose and total glycated hemoglobin
levels were not affected by pyridoxamine or enalapril
treatment. One major difference between groups was that
vehicle-treated mice had a high mortality (66.7%, Figure 5).
The combination of pyridoxamine with enalapril significantly
reduced the death rate (22% vs vehicle, Po0.05). Treatment
with enalapril alone did not improve survival. Infection was
the most prominent cause of animal death.
Albuminuria: A progressive increase in urine albumin
excretion was found in vehicle-treated diabetic db/db mice.
At 30–32 weeks of age, the urine albumin excretion rate in
diabetic db/db mice was 0.2770.13, a value significantly
higher than in diabetic mice at 24 weeks of age (0.170.04,
Po0.01). Combination therapy with pyridoxamine and
enalapril significantly reduced the progression of albumin-
uria (Figure 6). Enalapril as single agent did not decrease
albuminuria in mice with established DN.
Histology and morphometry: There was a progressive
increase in glomerular size in vehicle-treated diabetic db/db
mice (Figure 7a and d). This was associated with diffuse,
conspicuous expansion of the mesangial matrix. Glomerular
volume in diabetic db/db mice progressively increased from
2.470.03 105mm3, after 6 weeks of the diabetes, to
4.2770.4 105mm3 after 15 weeks of the diabetes and was
further increased to 670.5 105 mm3 after 22 weeks of the
diabetes. Combination therapy with enalapril and pyridox-
amine reduced both glomerular hypertrophy and mesangial
matrix expansion in diabetic db/db mice (Figure 7). Enalapril
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Figure 5 | Survival was increased in the combination enalapril
and pyridoxamine group compared to either the vehicle or
enalapril groups. *Po0.05 vs those in the combination therapy
group. Mice were followed for 22 weeks after the onset of diabetes
(B31 weeks of age). In all, 66.7% of the vehicle-treated died during
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Figure 6 | The increase in albuminuria was blunted in the
combination enalapril plus pyridoxamine group compared to
the vehicle or enalapril treated mice after 22 weeks of
hyperglycemia. *Po0.05 vs pretreatment (6 weeks after the onset
of hyperglycemia). The increase in albuminuria was prevented by
combination enalapril and pyridoxamine therapy. #Po0.05 vs
vehicle-treated mice at study end.
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Figure 7 | Glomerular lesions in diabetic db/db mice were
decreased after combination enalapril and pyridoxamine
therapy. (a) Severe glomerular lesions characterized by increased
glomerular size, mesangial sclerosis and cell proliferation were
presented in vehicle-treated mice after 22 weeks of hyperglycemia
(B31 weeks of age). (b) Glomerular hypertrophy was less
pronounced in the enalapril treatment group compared to the
vehicle-treatment group. (c) Glomerular histologic lesions were less
severe in the combination enalapril and pyridoxamine (Enalþ Pyri)
group. (d) Decreased glomerular volume in mice treated with
combination therapy. *Po0.05 vs vehicle-treated mice. (e) Decreased
mesangial area expansion in mice treated with combination therapy.
*Po0.05 vs vehicle-treated mice.
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treatment did not affect glomerular size or mesangial area
(Figure 7b, d, and e).
Decreased serum AGE levels in mice treated with
pyridoxamine plus enalapril
Serum AGE levels were significantly increased in vehicle-
treated diabetic db/db mice compared to age-matched db/þ
controls (Figure 8). Pyridoxamine and enalapril combination
therapy decreased, while enalapril alone did not affect AGE
levels.
Pyridoxamine decreased type IV collagen expression
The expansion of mesangial area in vehicle-treated B6 db/db
mice was associated with increased a1(IV) collagen mRNA
levels and type IV collagen accumulation in glomeruli (Figure
9a). Mice in the pyridoxamine-treatment group had reduced
mesangial area expansion, a1(IV) collagen mRNA levels and
type IV collagen deposits (Figure 9b and c). In addition,
pyridoxamine significantly reduced type IV collagen produc-
tion in both normal and high glucose conditions in cultured
mesangial cells isolated from diabetic db/db mice (Figure 10).
DISCUSSION
Both ACEi and angiotensin receptor blockade slowed, but do
not stop the progression of established DN in patients.19–22
The accumulation of AGE is a key factor in the pathogenesis
of DN.6,7 This led to the development of drugs that inhibit
the formation of AGE.23 Pyridoxamine is a newly discovered,
potent inhibitor of AGE and, has an excellent safety profile.
We undertook a study of its utility in the treatment of
established DN in db/db mice, a model of type II diabetes.
These mice have a leptin receptor mutation that causes
polyphagia, obesity, and insulin resistance followed by
diabetes mellitus.24,25 The phenotype of diabetes in db/db
mice depends on the genetic background. KsJ db/db mice
develop insulitis and hypoinsulinemia.26 On the other hand,
B6 db/db mice develop hyperglycemia with persistent
hyperinsulinemia and islet hypertrophy. Since the pattern
in B6 db/db mice resembles the diabetic phenotype
commonly seen in human type II diabetics, we selected
them as a model for pyridoxamine treatment. Since it has
been reported that the hyperglycemia in B6 db/db mice could
be transient and that glycemic levels were lower than that in
KsJ db/db mice, we studied a large cohort of B6 db/db mice.
We found that 75% of B6 db/db mice remained hypergly-
cemic, and had impaired glucose and insulin tolerance up to
the termination of this study at 8 months of age.18
Importantly, we found that B6 db/db mice with persistent
hyperglycemia developed progressive DN, and that urine
albumin excretion progressively increased only in that cohort
of B6 db/db mice with persistent hyperglycemia. Glomerular
hypertrophy and mesangial matrix expansion also progres-
sively worsened in the cohort with persistent hyperglycemia.
As seen in patients, we found that the inhibition of
angiotensin II with the combination of ACEi (benazepril)
and ARB (valsartan), before DN became established,
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Figure 8 | Decreased serum AGE levels in mice treated with
pyridoxamine plus enalapril. Serum AGE levels were measured at
killing (22 weeks after hyperglycemia) in mice treated with vehicle,
enalapril, and pyridoxamine plus enalapril. Levels from age-matched
dbþmice (non-diabetic heterozygote control for db/db mice) were
also determined. *Po0.05 vs vehicle-treated mice.
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Figure 9 | Decreased type IV collagen expression in the
pyridoxamine-treated group. (a) Decreased a1 type IV collagen
mRNA expression in renal cortex of pyridoxamine-treated
mice. *Po0.05 vs vehicle-treated mice. (b and c) Glomerular
type IV collagen accumulation was significantly reduced in
pyridoxamine-treated mice (immunofluorescence microscopy
 200).
0
2.5
5.0
7.5
Ty
pe
 IV
 c
ol
la
ge
n 
Control  Pyridoxamine
*
Mesangial cells in 5 mM glucose Mesangial cells in 30 mM glucose
0
0.5
1.0
1.5
2.0
Control  Pyridoxamine
*
(
g×
 
10
–
7 /c
el
l)
Ty
pe
 IV
 c
ol
la
ge
n 
(
g×
 
10
–
6 /c
el
l)
Figure 10 | Pyridoxamine decreased type IV collagen in cultured
mesangial cells. Mesangial cells were cultured under 5 mM (normal)
or 30 mM (high) glucose condition in the presence or absence of
pyridoxamine. Type IV collagen produced by the cells were measured
by enzyme-linked immunosorbent assay. Pyridoxamine significantly
decreased type IV collagen production by mesangial cells. *Po0.05
vs control.
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prevented the progression of DN in B6 db/db mice. Thus,
these mice provide a model for studying the pathogenesis of
type II DN and for evaluating the effect of new antinephro-
pathy drug(s).
Treatment with an ACEi and ARB combination did not
decrease blood pressure and the mice remained normoten-
sive. Thus, one limitation of this model is that hypertension,
one of the important factors contributing to nephropathy in
patients with diabetes, is not present in diabetic B6 db/db
mice. This is similar to findings in some patients with type II
diabetes.27
We found that B6 db/db mice developed DN after 6 weeks
of hyperglycemia, as evidenced by increased urine albumin
excretion and biopsy proven glomerular lesions. Albuminuria
and glomerular lesions were worsened with time in vehicle-
treated diabetic db/db mice. However, neither albuminuria
nor glomerular lesions progression was present in the
pyridoxamine-treated group after 15 weeks of diabetes. Thus,
we concluded that pyridoxamine treatment reduced the
progression of DN in B6 db/db mice.
Since ACEi’s and/or ANG II receptor blockers are
currently the standard treatment for DN, we expected that
the combination of pyridoxamine and enalapril would be
more effective, than either drug alone. However, enalpril as a
single treatment did not result in decreased progression of
DN in db/db mice. The dose of (10 mg/kg/day) enalapril used
in this study has been shown to reduce albuminuria in
diabetic rats.28–30 Thus, it may be that other factors may
contribute to the lack of effect of enalapril. Interestingly, we
have preliminary data showing that captopril alone was not
effective. However, since a combination of benazepril and
valsartan successfully prevented the progression of DN in B6
db/db mice, these data suggest that either there are
differences between ACEi’s or that a more complete
inhibition of ANG II may be required for the treatment of
DN in db/db mice. In support of this postulate are the
findings that a combination of ACEI and ANG II receptor
blocker was more effective than ACEI alone in type II diabetic
patients with nephropathy.31
We found that the combination of pyridoxamine and
enalapril significantly reduced the progression of albumin-
uria and glomerular lesions in diabetic db/db mice.
Furthermore, the combination treatment significantly re-
duced mortality. Infection was the principal cause of death in
all groups of mice. The mechanism for the decreased
mortality in the group treated with the combination of
pyridoxamine and enalapril remains unclear.
The effects of pyridoxamine on DN were thought to be
related to inhibition of the formation of tissue AGEs and
advanced lipoxidation end products, to improvement of the
altered redox status in diabetes, and to reduction of serum
lipid levels.16,17,23 We found that combination treatment of
pyridoxamine and enalapril decreased serum AGE levels in
diabetic db/db mice while enalapril treatment alone did not
have this effect. Interestingly, we found that type IV collagen
mRNA expression in renal cortex and type IV collagen
accumulation in glomeruli was significantly reduced in
pyridoxamine-treated B6 db/db mice. Using mesangial cells
isolated from diabetic db/db mice, we found that high
glucose in the culture medium led to significantly increased
type IV collagen production. Pyridoxamine suppressed type
IV collagen production by diabetic db/db mice mesangial
cells in the presence of both elevated and normal glucose
concentrations. Since mesangial cells isolated from diabetic
db/db mice have been shown to exhibit phenotypic changes
favoring the development and progression of diabetic
glomerular lesions, this may partially explain the effect of
pyridoxamine on cells under normal glucose condition.32
Thus, pyridoxamine may have a direct effect on type IV
collagen production by mesangial cells.
In summary, we found that pyridoxamine prevented the
progression of established DN and decreased mortality in B6
db/db mice, a model of type II diabetes.
MATERIALS AND METHODS
Experimental design
The purpose of these experiments was three-fold: (1) determine
whether B6 db/db mice as a model of type II diabetes mellitus
resembled that of patients, clinically, histologically and response to
ACEi and/or ARB therapy, now considered to be standard-of-care;
(2) determine whether pyridoxamine, an inhibitor of AGE
formation was a safe and effective adjunct to ACEi treatment; and
(3) determine whether pyridoxamine would add to the benefit of
ACEi treatment.
Female B6 db/db mice were obtained from Jackson Laboratories
(Bar Harbor, ME, USA). Because of the limited supply of these mice,
the experiments were performed on mice obtained at three different
times (Table 1, Time lines). In the first set of experiments (group 1),
we tested the effectiveness of a combination of ACEi and ARB on the
development and progression of DN. Mice with stable hypergly-
cemia (X200 mg/dl) between 8 and 10 weeks of age were randomized
to receive 16 weeks of either benazeprilþ valsartan (n¼ 10, 15 mg/kg/
day of each drug in drinking water) or vehicle (n¼ 9).
In the second set of experiments (group 2), we tested the
effectiveness of pyridoxamine on established DN. An open renal
biopsy, from the lower pole of the left kidney, was performed on
mice 6 weeks after the onset of hyperglycemia. Anesthesia was
provided by ketamine and xylazine. We obtainedX20 glomeruli per
biopsy. One week after biopsy, mice with glomerular lesions,
sustained hyperglycemia and an elevated albumin/creatinine ratio
were randomized to receive either pyridoxamine (n¼ 6, 250 mg/kg/
day in drinking water, provided by Biostratum Inc., Durham, NC,
USA) or vehicle (n¼ 6). Mice were housed individually and the
concentration of pyridoxamine in drinking water was adjusted daily
based on the water intake. Mice were followed for 8 weeks. Blood
pyridoxamine and lipid levels were determined at killing. Fifty
percent of the mice died during the early follow-up period, due
mostly to infection, and were not included in analyses. Plasma
pyridoxamine concentrations were measured by reverse phase-high
performance liquid chromatography with excitation and emission
wavelengths of 293 and 393 nm as previously described.16
Since the second set of the experiments revealed that all female
B6 db/db mice developed nephropathy after 6 weeks of hyper-
glycemia and the rate of infection was high after renal biopsy, we did
not perform this procedure in the third set of animals (group 3).
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The mice were followed for 6 weeks after the onset of diabetes and
were then randomized to receive: (1) enalapril (10 mg/kg/day) plus
pyridoxamine (250 mg/kg/day), n¼ 11; (2) enalapril (10 mg/kg/day)
plus pyridoxamine (100 mg/kg/day), n¼ 9; (3) enalapril (10 mg/kg/
day), n¼ 10; 4. Vehicle, n¼ 15. Mice were treated for 16 weeks.
Glycemia and glycosuria were monitored in animals twice per
week in all experiments. Mice in which glycemic levels fell to
o200 mg/dl over a period of 3 consecutive weeks, an event which
occurred most often within 3 weeks after the onset of hyperglycemia,
were excluded from the studies and analyses. Total glycosylated
hemoglobin was examined at the end of study on whole blood by
boronate affinity chromatography (Sigma, St Louis, MO, USA).
Urine samples were collected weekly. Blood pressure was recorded 1
week before killing using a sensor cuff device.33 Serum AGE levels
were measured by a competitive enzyme-linked immunosorbent
assay based on an anti-CML monoclonal antibody (4G9), as
previously described.34
Urine albumin was measured by enzyme-linked immunosorbent
assay using a kit from Bethyl Laboratory Inc. (Houston, TX, USA),
as previously described.33 Urine creatinine levels were measured in
the same samples and the urine albumin excretion rate was
expressed as the ratio of albumin to creatinine.
Renal histology and morphometry
At killing, the kidneys were perfused with a saline solution and
subsequently perfuse fixed in situ with 4% paraformaldehyde. The
tissues were embedded in glycol methacrylate, cut at a thickness of
2 mm and stained with periodic acid Schiff.33 The glomerular
volume and mesangial area were determined by examining plastic-
embedded sections using a digitizing tablet and video camera as
previously described.33 The relative mesangial area was expressed as
mesangial/glomerular surface area (%).
mRNA levels
Total RNA was isolated from renal cortex of the second set of
animals, as described.33 a1 type IV collagen mRNA levels were
determined by real-time polymerase chain reaction (PCR).33 Briefly,
equal amounts of RNA from each sample were reverse transcribed
with specific primers and amplified using the TaqMan one step
reverse transcriptase-polymerase chain reaction master mix reagents
kit and ABI Prism 7700 sequence detection system (Perkin Elmer
Applied Biosystems, Wellesley, MA, USA). Taqman ribosomal RNA
control reagents kits were used to measure the expression of 18S
ribosomal RNA genes. The levels of a1 type IV collagen mRNA
expression were normalized to 18S mRNA levels.
Type IV collagen immunofluorescence staining
Frozen kidney sections from the second set of animals were cut at a
thickness of 5 mm. Sections were incubated with cold acetone for
10 min and coated with a rabbit anti-type IV collagen (Biodesign,
Kennebunkport, ME, USA) followed by a biotin-conjugated goat
anti-rabbit IgG (Sigma, Saint Louis, MO, USA) and streptavidin-
conjugated fluorescein isothiocyanate (Zymed Laboratories Inc., San
Francisco, CA, USA).33 Sections were examined by an investigator
who was blinded to the experimental groups.
Mesangial cell type IV collagen
Mesangial cells were isolated from microdissected glomeruli and
characterized as previously described.34 In all, 30 000 cells were
seeded in each well of a 24-well plate in medium containing 20%
Table 1 | Timeline of the experiments
Group 1 Benazepril+Valsartan (n =10)
Age (weeks) 8 10
Onset of diabetes
24 26
Sacrifice
Treatment start
Vehicle (n =10)
Length of treatment  (16 weeks)
Group 2 Pyridoxamine(n =6)
Age (weeks) 8 10
Onset of diabetes
23 25
SacrificeVehicle (n =6)
14 16
Renal biopsy
Treatment start
one week after biopsy
Length of treatment 
(8 weeks)
Group 3 Enalapril+pyridoxamine (n=9)
Age (weeks) 8 10
Onset of diabetes
30 32
Sacrifice
Enalapril (n =10)
14 16
Treatment start
Length of treatment 
(16 weeks)
Vehicle (n =15)
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serum to examine the effect of pyridoxamine on the production of
type IV collagen by mesangial cells. After 24 h, cells were switched to
normal glucose (5 mM) or high glucose (30 mM) medium containing
0.1% bovine serum albumin in the presence or absence of 30 ng/ml
of pyridoxamine. Supernatant and cell lysate were collected 48 h
after treatment. Type IV collagen in the supernatant and cell lysate
were assayed by enzyme-linked immunosorbent assay, as previously
described.35
Statistical analysis
Values were expressed as mean7s.e. The two-tailed unpaired t-test
was used to evaluate the differences of means for data obtained from
mice treated with pyridoxamine or vehicle. The levels of significance
was tested at Po0.05. One way analysis of variance and post t-test
were used for the comparisons of differences among groups of the
third set of experiments. Survival curve was analyzed by the Prism
software.
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